首页> 美国卫生研究院文献>Acta Naturae >Regulation of the Target Protein (Transgene) Expression in the Adenovirus Vector Using Agonists of Toll-Like Receptors
【2h】

Regulation of the Target Protein (Transgene) Expression in the Adenovirus Vector Using Agonists of Toll-Like Receptors

机译:使用Toll样受体激动剂调节腺病毒载体中靶蛋白(转基因)的表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Replication-defective adenoviral vectors are effective molecular tools for both gene therapy and gene vaccination. Using such vectors one can deliver and express target genes in different epithelial, liver, hematopoietic and immune system cells of animal and human origin. The success of gene therapy and gene vaccination depends on the production intensity of the target protein encoded by the transgene. In this work, we studied influence of Toll-like receptors (TLR) agonists on transduction and expression efficacy of adenoviral vectors in animal and human antigen-presenting cells. We found that agonists of TLR2, 4, 5, 7, 8 and 9 significantly enhance a production of the target protein in cells transduced with adenoviral vector having the target gene insert. The enhancement was observed in dendritic cells and macrophages expressing cytoplasmic (GFP), membrane (HA) or secretory (SEAP) proteins encoded by the respective rAd-vectors. Experiments in mice showed that enhancement of the transgene expression can be achieved in the organism of animals using a pharmaceutical-grade TLR4-agonist. In contrast to other TLR-agonists, the agonist of TLR3 substantially suppressed the expression of transgene in cellstransduced with adenoviral vectors having insert of GFP or SEAP target genes.We propose that the enhancement of transgene expression is linked to theactivation of MyD88→ NF-kB, while the inhibition of transgene expressiondepends on TRIF→ IRF signaling pathways. Both of these pathways jointlyexploited by TLR4-agonists lead to the enhancement of transgene expression dueto the dominant role of the MyD88→ NF-kB signaling.
机译:复制缺陷型腺病毒载体是用于基因治疗和基因疫苗接种的有效分子工具。使用这种载体,可以在动物和人类来源的不同上皮,肝脏,造血和免疫系统细胞中递送和表达靶基因。基因治疗和基因疫苗接种的成功取决于转基因编码的靶蛋白的生产强度。在这项工作中,我们研究了Toll样受体(TLR)激动剂对腺病毒载体在动物和人抗原呈递细胞中的转导和表达功效的影响。我们发现TLR2、4、5、7、8和9的激动剂在具有目标基因插入物的腺病毒载体转导的细胞中显着增强了目标蛋白质的产生。在表达由相应rAd载体编码的胞质(GFP),膜(HA)或分泌性(SEAP)蛋白的树突细胞和巨噬细胞中观察到增强。小鼠实验表明,使用药物级TLR4-激动剂可在动物体内实现转基因表​​达的增强。与其他TLR激动剂相反,TLR3激动剂基本上抑制了转基因在细胞中的表达用具有GFP或SEAP靶基因插入物的腺病毒载体转导。我们建议转基因表达的增强与激活MyD88→NF-kB,同时抑制转基因表达取决于TRIF→IRF信号通路。这两种途径共同TLR4激动剂开发的产物可导致转基因表达增强在MyD88→NF-kB信号传导中起主导作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号